Bank of New York Mellon Corp cut its holdings in Pfizer, Inc. (NYSE:PFE) by 8.3% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 64,428,385 shares of the biopharmaceutical company’s stock after selling 5,810,192 shares during the period. Pfizer accounts for about 0.6% of Bank of New York Mellon Corp’s holdings, making the stock its 25th biggest position. Bank of New York Mellon Corp owned 3.85% of Pfizer worth $2,164,150,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Northstar Group Inc. increased its holdings in shares of Pfizer by 0.4% during the 2nd quarter. Northstar Group Inc. now owns 8,602 shares of the biopharmaceutical company’s stock worth $289,000 after buying an additional 35 shares during the last quarter. River Wealth Advisors LLC increased its holdings in shares of Pfizer by 0.3% during the 2nd quarter. River Wealth Advisors LLC now owns 15,818 shares of the biopharmaceutical company’s stock worth $531,000 after buying an additional 55 shares during the last quarter. Meridian Wealth Management LLC increased its holdings in shares of Pfizer by 0.5% during the 2nd quarter. Meridian Wealth Management LLC now owns 11,966 shares of the biopharmaceutical company’s stock worth $402,000 after buying an additional 57 shares during the last quarter. Stone House Investment Management LLC increased its holdings in shares of Pfizer by 0.9% during the 1st quarter. Stone House Investment Management LLC now owns 7,164 shares of the biopharmaceutical company’s stock worth $245,000 after buying an additional 66 shares during the last quarter. Finally, Telemus Capital LLC increased its holdings in shares of Pfizer by 0.5% during the 2nd quarter. Telemus Capital LLC now owns 17,888 shares of the biopharmaceutical company’s stock worth $601,000 after buying an additional 92 shares during the last quarter. Institutional investors own 69.34% of the company’s stock.

Shares of Pfizer, Inc. (PFE) opened at $35.37 on Monday. The firm has a market cap of $210,830.00, a PE ratio of 14.15, a P/E/G ratio of 2.50 and a beta of 1.01. Pfizer, Inc. has a 12 month low of $30.51 and a 12 month high of $36.78. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.02. The firm had revenue of $13.17 billion for the quarter, compared to analyst estimates of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. Pfizer’s quarterly revenue was up .9% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.61 earnings per share. analysts expect that Pfizer, Inc. will post 2.6 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Friday, November 10th will be paid a dividend of $0.32 per share. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $1.28 annualized dividend and a yield of 3.62%. Pfizer’s dividend payout ratio (DPR) is 78.53%.

A number of analysts have recently commented on PFE shares. BMO Capital Markets upgraded Pfizer from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $33.00 to $37.00 in a report on Wednesday, August 2nd. UBS AG reaffirmed a “buy” rating and set a $38.00 price target on shares of Pfizer in a research report on Monday, July 31st. ValuEngine raised shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Friday, October 6th. Zacks Investment Research cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Finally, Morgan Stanley raised shares of Pfizer from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $35.00 to $39.00 in a research report on Wednesday, September 20th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $38.48.

COPYRIGHT VIOLATION WARNING: This article was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/11/20/bank-of-new-york-mellon-corp-has-2-16-billion-holdings-in-pfizer-inc-pfe.html.

In other Pfizer news, EVP Frank A. Damelio sold 94,409 shares of the firm’s stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $34.00, for a total value of $3,209,906.00. Following the sale, the executive vice president now owns 337,389 shares in the company, valued at $11,471,226. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Ian C. Read sold 197,168 shares of the firm’s stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $34.00, for a total transaction of $6,703,712.00. Following the completion of the sale, the chief executive officer now owns 580,318 shares in the company, valued at approximately $19,730,812. The disclosure for this sale can be found here. In the last quarter, insiders have sold 366,557 shares of company stock worth $12,532,406. 0.06% of the stock is owned by company insiders.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.